Table 1.
Baseline clinical characteristics of the study population (N = 184). SD, standard deviation; SCC, squamous cell carcinoma.
| n (%) | |
|---|---|
| age at diagnosis (years) | |
| mean (s.d.) | 48 (13) |
| median (range) | 46 (17–78) |
| serum samples per woman (n) | |
| mean (s.d.) | 4 (2.5) |
| median (range) | 3 (2–12) |
| follow-up time (days) | |
| mean (s.d.) | 907 (864) |
| median (range) | 725 (18–6637) |
| tumour HPV DNAa | |
| HPV16 | 69 (57.5) |
| HPV18 | 27 (22.5) |
| other HPV types | 24 (20.0) |
| tumour stageb | |
| T1 | 87 (47.3) |
| T2 | 60 (32.6) |
| T3 | 15 (8.2) |
| T4 | 12 (6.5) |
| nodal stageb | |
| N0 | 108 (58.7) |
| N1 | 52 (28.3) |
| resection marginb | |
| R0 | 98 (53.3) |
| R1 | 21 (11.4) |
| R2 | 2 (1.1) |
| histologyb | |
| SCC | 138 (75.0) |
| adenocarcinoma | 31 (16.8) |
| follow-up statusb | |
| no relapse/residual disease | 110 (59.8) |
| relapse/residual disease | 63 (34.2) |
a120 HPV genotyping results for 114 women available (due to multiple HPV DNA positivity in four tumours).
bDoes not add up to 100% due to missing data.